Podcast 21 Jun 2024
How ADCs can deliver death cap mushroom toxins to treat cancer
Listen to our conversation with Heidelberg Pharma about its lead amanitin-based ADC product candidate, HDP-101.
Cancer
- Latest Posts
Best in Biotech 13 Jun 2024
Eight companies tackling cancer with allogeneic cell therapy in 2024
Unlike autologous cell therapy, where the patient’s own cells are used, allogeneic cell therapy companies leverage donor cells, which can come from various sources such as bone marrow or umbilical cord blood. In allogeneic cell therapy, healthy donor cells are harvested, processed, and then infused into the patient. These donor cells can differentiate into various […]
The untapped power of multivariate analysis for target identification in cancer drug discovery
Discover how multivariate analysis is transforming target identification in cancer drug discovery by moving beyond traditional methods.
In Depth 10 Jun 2024
ASCO 2024: The latest advances in oncology clinical trials
Biotechs from all over the country as well as other parts of the world showcased recent pipeline advancements in oncology clinical trials at ASCO 2024.
Best in Biotech 6 Jun 2024
Eight biotech companies advancing the field of siRNA
Explore the growing sector of siRNA and discover eight biotech companies spearheading this innovative field.
In Depth 5 Jun 2024
Evolving standards of care: new treatments for cervical cancer
New treatments for cervical cancer aim to broaden therapeutic options, and improve current standards of care for patients.
ADVERTISEMENT
ADVERTISEMENT
In Depth 30 May 2024
Covalent biologics: a new class of drugs on the horizon
The field of covalent biologics has made headway recently, as the only biotech in the space has bagged $100 million to move its pipeline to the clinic.
Best in Biotech 30 May 2024
Stem cell therapy’s avant-garde: Eight companies leading the way
Stem cell therapy has gained traction over the recent years and the market is growing, discover eight companies advancing the field.
In Depth 22 May 2024
The undruggable cancer target: KRAS inhibitors move ahead in the clinic
Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio’s spinout.
Best in Biotech 21 May 2024
Eight companies spearheading Philadelphia’s biotech industry
Often called the Cellicon Valley due to its focus on cell and gene therapy, discover eight Philadelphia biotech companies to know about.
Cell avidity-tuning ensures safe CAR-T therapy for solid tumors
Learn more about the potential of cell avidity in designing potent and safe CAR-T treatments for solid tumors.
In Depth 9 May 2024
BTK inhibitors: can these drugs tackle cancer and autoimmunity?
BTK inhibitors were first approved over a decade ago to treat a rare blood cancer. Now, they are in the running to treat a host of autoimmune diseases.
ADVERTISEMENT
